Racial and Ethnic Diversity in Clinical Trials for Disease Modifying Drugs in Parkinson Disease: A Systematic Review & Meta-Analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Racial and ethnic minorities are severely underrepresented in Parkinson's Disease (PD) clinical trials for new therapies. This study highlights the need for greater diversity in PD research to ensure equitable treatment development.
Area Of Science
- Neurology
- Clinical Trials
- Health Equity
Background
- Historic underrepresentation of non-White participants in Parkinson's Disease (PD) research.
- Lack of exploration in disease-modifying therapy trials.
Purpose Of The Study
- Evaluate racial/ethnic minority representation in PD clinical trials.
- Focus on double-blind, randomized, placebo-controlled trials (DBRCTs).
Main Methods
- Systematic search of four electronic databases.
- Included DBRCTs for PD disease modification.
- Data extraction following PRISMA guidelines.
Main Results
- 37 DBRCTs and 11,022 patients analyzed.
- Only 51.4% reported race/ethnicity.
- White participants comprised 98% of the study population.
Conclusions
- Significant underrepresentation of racial/ethnic minorities in PD DBRCTs.
- Need for increased diversity in PD research.
- Ensuring equitable development of PD therapies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
The cephalic phase is a conditioned or learned response to familiar foods. Our appetite or desire for a particular food modifies the preparatory responses directed by the brain. Individuals may produce more saliva and stomach...